Locke Lord LLP advised Biohaven Pharmaceutical Holding Company on the deal. Biohaven Pharmaceutical Holding Company announced a $60 million Series A Preferred equity financing of BioShin…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
